MassBio's BD/Finance Working Group invites you to hear from a distinguished panel of venture, biotech and large pharma leaders who will discuss their views on the current trends in oncology dealmaking.
Panelists will address key questions including:
- How is the turbulent market impacting a company’s decision to Financing/IPO vs Partnering?
- What are the changing views on Platform vs. Asset deals?
- How is large pharma changing the ways that assets are valued?
- Immuno-oncology! What’s biotech and pharma’s experience in making deals in this highly competitive and dynamic space and how is the process different from our traditional oncology deals?
Join the discussion, ask your own questions and share your experiences.